Real-time Estimate
Cboe BZX
08:10:21 26/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
9.48
USD
|
-1.25%
|
|
+13.04%
|
+189.78%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,225
|
1,043
|
901.4
|
304.9
|
1,111
|
-
|
-
|
Enterprise Value (EV)
1 |
941.1
|
728.4
|
689.6
|
234.8
|
747.9
|
714
|
606.4
|
P/E ratio
|
-7.4
x
|
-4.96
x
|
-2.61
x
|
-0.85
x
|
-5.63
x
|
-8.26
x
|
-209
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
245
x
|
5.11
x
|
6.78
x
|
4.51
x
|
2.78
x
|
EV / Revenue
|
-
|
-
|
187
x
|
3.94
x
|
4.56
x
|
2.9
x
|
1.52
x
|
EV / EBITDA
|
-6.89
x
|
-3.53
x
|
-2.29
x
|
-0.98
x
|
-4.32
x
|
-5.24
x
|
-12
x
|
EV / FCF
|
-8.3
x
|
-4.15
x
|
-2.67
x
|
-0.95
x
|
-5.84
x
|
-9.92
x
|
7.05
x
|
FCF Yield
|
-12%
|
-24.1%
|
-37.4%
|
-105%
|
-17.1%
|
-10.1%
|
14.2%
|
Price to Book
|
-
|
3.5
x
|
4.31
x
|
2.52
x
|
6.96
x
|
6.08
x
|
4.16
x
|
Nbr of stocks (in thousands)
|
43,566
|
50,295
|
60,909
|
94,382
|
1,15,764
|
-
|
-
|
Reference price
2 |
28.13
|
20.74
|
14.80
|
3.230
|
9.600
|
9.600
|
9.600
|
Announcement Date
|
16/02/21
|
22/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
3.686
|
59.61
|
164
|
246.4
|
399.2
|
EBITDA
1 |
-43.06
|
-136.5
|
-206.1
|
-301
|
-240.3
|
-173.2
|
-136.4
|
-50.44
|
EBIT
1 |
-43.13
|
-136.6
|
-206.5
|
-301.6
|
-241.1
|
-175.2
|
-126
|
-9.899
|
Operating Margin
|
-
|
-
|
-
|
-8,183.04%
|
-404.49%
|
-106.79%
|
-51.15%
|
-2.48%
|
Earnings before Tax (EBT)
1 |
-
|
-135.7
|
-206.4
|
-311.5
|
-259
|
-190.9
|
-138.7
|
-8.4
|
Net income
1 |
-
|
-135.7
|
-206.4
|
-311.5
|
-262.1
|
-191
|
-138.7
|
-8.4
|
Net margin
|
-
|
-
|
-
|
-8,449.76%
|
-439.79%
|
-116.41%
|
-56.28%
|
-2.1%
|
EPS
2 |
-
|
-3.800
|
-4.180
|
-5.660
|
-3.780
|
-1.705
|
-1.162
|
-0.0460
|
Free Cash Flow
1 |
-43.13
|
-113.3
|
-175.6
|
-258
|
-247.5
|
-128
|
-72
|
86
|
FCF margin
|
-
|
-
|
-
|
-7,000.76%
|
-415.2%
|
-78.03%
|
-29.23%
|
21.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
16/02/21
|
22/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
0.725
|
2.961
|
2.781
|
5.19
|
38.11
|
13.53
|
49.57
|
28.34
|
35.98
|
46.66
|
55
|
63
|
EBITDA
|
-71.15
|
-62.48
|
-
|
-104.6
|
-68.26
|
-76.09
|
-66.56
|
-36.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-71.29
|
-62.63
|
-65.83
|
-104.7
|
-68.42
|
-76.26
|
-66.76
|
-36.9
|
-61.17
|
-31.62
|
-53.84
|
-48.19
|
-41.18
|
-35.4
|
-31.6
|
Operating Margin
|
-
|
-
|
-
|
-14,448%
|
-2,310.84%
|
-2,742.36%
|
-1,286.38%
|
-96.84%
|
-452.23%
|
-63.79%
|
-189.96%
|
-133.95%
|
-88.26%
|
-64.36%
|
-50.16%
|
Earnings before Tax (EBT)
1 |
-71.33
|
-64.32
|
-67.41
|
-107.7
|
-72.02
|
-80.1
|
-70.99
|
-41.74
|
-66.26
|
-35.06
|
-58.03
|
-52.07
|
-45.83
|
-35.4
|
-31.6
|
Net income
1 |
-71.33
|
-64.32
|
-67.41
|
-107.7
|
-72.02
|
-80.1
|
-70.99
|
-44.76
|
-66.28
|
-35.38
|
-58.03
|
-52.07
|
-45.73
|
-35.4
|
-31.6
|
Net margin
|
-
|
-
|
-
|
-14,856.41%
|
-2,432.25%
|
-2,880.26%
|
-1,367.84%
|
-117.47%
|
-490.05%
|
-71.38%
|
-204.78%
|
-144.71%
|
-98.01%
|
-64.36%
|
-50.16%
|
EPS
2 |
-1.420
|
-1.270
|
-1.310
|
-1.890
|
-1.180
|
-1.310
|
-1.160
|
-0.7300
|
-0.7200
|
-0.3200
|
-0.5225
|
-0.4650
|
-0.4175
|
-0.3000
|
-0.3000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/22
|
05/05/22
|
04/08/22
|
08/11/22
|
28/02/23
|
09/05/23
|
08/08/23
|
03/11/23
|
27/02/24
|
14/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
63.3
|
284
|
315
|
212
|
70.1
|
363
|
397
|
505
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.1
|
-113
|
-176
|
-258
|
-247
|
-128
|
-72
|
86
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-72.6%
|
-123%
|
-176%
|
-152%
|
-79.7%
|
-27%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
5.920
|
3.430
|
1.280
|
1.380
|
1.580
|
2.310
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.32
|
1
|
0.33
|
0.43
|
3
|
4
|
5
|
Capex / Sales
|
-
|
-
|
-
|
9.03%
|
0.72%
|
1.83%
|
1.62%
|
1.25%
|
Announcement Date
|
19/03/20
|
16/02/21
|
22/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Average target price
19
USD Spread / Average Target +97.92% Consensus |
1st Jan change
|
Capi.
|
---|
| +189.78% | 111.13Cr | | +16.84% | 12TCr | | +20.23% | 12TCr | | +22.07% | 2.7TCr | | -20.97% | 2.04TCr | | -16.73% | 1.64TCr | | -18.44% | 1.59TCr | | -44.35% | 1.56TCr | | +63.24% | 1.49TCr | | +0.96% | 1.36TCr |
Bio Therapeutic Drugs
|